A Study of Zongertinib in People With Lung Cancer

Full Title

Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared with Standard of Care in Patients with Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Jamie Chaft’s office at 646-497-9176.

Protocol

26-122

Phase

Phase III (phase 3)

Disease Status

Relapsed or Refractory

Investigator

Jamie E. Chaft
Fernando Santini

Diseases

Lung Cancer › Lung Cancer, Non-Small Cell

Locations

Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau

ClinicalTrials.gov ID

NCT07195695

ClinicalTrials.gov

Visit ClinicalTrials.gov for full clinical trial description